Atomo Diagnostics will be showcasing their range of user-centred rapid diagnostic test platforms at Arab Health 2023.
Web
A global expert in the user-centred design of rapid diagnostics, the company will be joining the ABHI UK Pavilion to demonstrate how their simple and low-cost solutions can deliver "better user experience, more accurate results and better healthcare outcomes".
Atomo Diagnostics has developed a technology based on the philosophy that fast, accurate point of care testing should be simple and intuitive, focusing on how diagnostic tests operate in the hands of users to improve ease of use and reduce error rates.
The recipient of multiple international design awards, Atomo creates devices that address the problems commonly associated with standard multi-component rapid diagnostic test kits.
Atomo’s Rapid Diagnostic Test (RDT) platforms offer all-in-one convenience with a built-in safety lancet, unique sample collection feature, single action sample and buffer delivery system, and interlocked user steps. The design and built-in features of Atomo’s products are designed to make them simpler to use than standard multi-component test kits, with less scope for user errors.
The company offers an integrated, blood-based rapid diagnostic test (RDT) for HIV screening, recognised for its design, performance and ease-of-use, with an accuracy of 99.6%. Their product range also encompasses accurate point of care diagnostic platforms that can be used in testing for infectious diseases such as Covid-19, allergy sensitivities, wellness, women’s health, men’s health, sexual health, heart health and other applications.
Atomo has recently introduced a Swab Platform to market, which expands their product range beyond blood-based testing and has been developed to improve usability and performance of traditional swab-based rapid tests.
Their products are currently approved for distribution in over 40 countries.
John Kelly, CEO of Atomo Diagnostics, commented: “Our innovative rapid test solutions deliver unmatched usability and simplicity in point-of-care testing, and have demonstrated excellent performance for both professional and home use. Our flagship HIV Self Test is prequalified by the WHO and registered in more than 20 countries. Beyond HIV, Atomo works with partners to commercialise tests on its devices for other applications, with commercialised tests delivering early detection of pregnancy and differentiating between viral and bacterial infection in primary care settings. Our unique devices and functionality are increasingly being recognised as a solution to decentralised testing needs and we continue to seek partners looking to improve the usability and performance of their POC tests. We are excited to be joining ABHI at this year’s Arab Health Exhibition where we look forward to showcasing our innovative products and technologies, as well as making new connections and forming new partnerships with global distributors.”
The Arab Health Exhibition & Congress is taking place from 30 January – 2 February 2023 at the Dubai Convention and Exhibition Centre. Throughout the exhibition, Atomo Diagnostics will be located on the ABHI UK Pavilion – Hall 2, Stand H50.